or Try an Advanced Search...

    Technical Analysis for ANIX - Anixa Biosciences, Inc.

    Grade Last Price % Change Price Change
    F 2.85 -2.06% -0.06
    ANIX closed down 2.06 percent on Friday, May 17, 2024, on 66 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Jun 7
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ANIX trend table...
    Date Alert Name Type % Chg
    BB Squeeze Ended Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -2.06%
    Bollinger Band Squeeze Range Contraction -2.06%
    Stochastic Reached Oversold Weakness -2.06%
    Oversold Stochastic Weakness -2.06%
    20 DMA Resistance Bearish -2.73%
    Bollinger Band Squeeze Range Contraction -2.73%
    Outside Day Range Expansion -2.73%
    Older End-of-Day Signals for ANIX ...

       Recent Intraday Alerts

    Alert Time
    Lower Bollinger Band Support 1 day ago
    Possible NR7 1 day ago
    Down 2 % 1 day ago
    Fell Below Previous Day's Low 1 day ago
    Down 1% 1 day ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ANIX Chart by TradingView
    Basic chart:

    Profile

    Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer. Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.
    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Emerging Technologies Cancer Treatment Gene Therapy Leukemia Blood Test Amines Chimeric Antigen Receptor Immune Response

    Is ANIX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 9 Anixa expands cancer vaccine collaboration with Cleveland Clinic
    May 8 Anixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccines
    May 8 Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
    May 7 Sidoti Events, LLC's Virtual May Micro-Cap Conference
    May 6 Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
    Apr 30 Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
    Apr 18 Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
    Mar 14 Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
    Mar 11 Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
    Feb 17 We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth
    See more ANIX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.13
    52 Week Low 2.75
    Average Volume 112,082
    200-Day Moving Average 3.54
    50-Day Moving Average 3.16
    20-Day Moving Average 3.00
    10-Day Moving Average 2.95
    Average True Range 0.17
    RSI (14) 41.52
    ADX 18.64
    +DI 10.27
    -DI 22.23
    Chandelier Exit (Long, 3 ATRs) 2.90
    Chandelier Exit (Short, 3 ATRs) 3.33
    Upper Bollinger Bands 3.18
    Lower Bollinger Band 2.81
    Percent B (%b) 0.1
    BandWidth 12.20
    MACD Line -0.08
    MACD Signal Line -0.08
    MACD Histogram 0.0019
    Fundamentals Value
    Market Cap 90.34 Million
    Num Shares 31.7 Million
    EPS -0.32
    Price-to-Earnings (P/E) Ratio -8.91
    Price-to-Sales 680.79
    Price-to-Book 5.87
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.99
    Resistance 3 (R3) 2.99 2.96 2.96
    Resistance 2 (R2) 2.96 2.92 2.95 2.95
    Resistance 1 (R1) 2.90 2.90 2.89 2.90 2.95
    Pivot Point 2.87 2.87 2.86 2.86 2.87
    Support 1 (S1) 2.81 2.83 2.80 2.81 2.75
    Support 2 (S2) 2.78 2.81 2.77 2.75
    Support 3 (S3) 2.72 2.78 2.74
    Support 4 (S4) 2.72